These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 4614981

  • 1. Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom.
    Fischer PA, Schneider E, Jacobi P, Maxion H.
    Eur Neurol; 1974; 12(5-6):360-8. PubMed ID: 4614981
    [No Abstract] [Full Text] [Related]

  • 2. Melanocyte-stimulating hormone-release inhibiting hormone as a antidepressant. A pilot study.
    Ehrensing RH, Kastin AJ.
    Arch Gen Psychiatry; 1974 Jan; 30(1):63-5. PubMed ID: 4587068
    [No Abstract] [Full Text] [Related]

  • 3. Hypothalamic releasing factors and Parkinson disease.
    Chase TN, Woods AC, Lipton MA, Morris CE.
    Arch Neurol; 1974 Jul; 31(1):55-6. PubMed ID: 4209275
    [No Abstract] [Full Text] [Related]

  • 4. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J, van Praag HM, Schut D, Nienhuis RJ, Lakke JP.
    Eur Neurol; 1974 Jul; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract] [Full Text] [Related]

  • 5. Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
    Caraceni T, Parati EA, Girotti F, Celano I, Frigerio C, Cocchi D, Müller EE.
    Psychopharmacology (Berl); 1979 Jun 21; 63(3):217-22. PubMed ID: 39308
    [Abstract] [Full Text] [Related]

  • 6. Letter: Lithium and M.R.I.H. in tardive dyskinesia.
    Ehrensing RH.
    Lancet; 1974 Dec 14; 2(7894):1459-60. PubMed ID: 4140382
    [No Abstract] [Full Text] [Related]

  • 7. [MIF (melanocyte-stimulating hormone release-inhibiting factor) and Parkinson's disease].
    Carolei A, Meco G, Casacchia M, Agnoli A.
    Acta Neurol (Napoli); 1976 Dec 14; 31(4):475-8. PubMed ID: 16441
    [No Abstract] [Full Text] [Related]

  • 8. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease.
    Martin WE, Loewenson RB, Resch JA, Baker AB.
    Neurology; 1974 Oct 14; 24(10):912-9. PubMed ID: 4606107
    [No Abstract] [Full Text] [Related]

  • 9. Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides.
    Castensson S, Sievertsson H, Lindeke B, Sum CY.
    FEBS Lett; 1974 Aug 15; 44(1):101-5. PubMed ID: 4212370
    [No Abstract] [Full Text] [Related]

  • 10. Production of MSH-release-inhibiting hormone by a particulate preparation of hypothalami: mechanisms of oxytocin inactivation.
    Walter R, Griffiths EC, Hooper KC.
    Brain Res; 1973 Oct 12; 60(2):449-57. PubMed ID: 4587290
    [No Abstract] [Full Text] [Related]

  • 11. Morphological and biochemical studies on liver biopsies of parkinsonian patients treated with levodopa and decarboxylase inhibitor.
    Nevalainen T, Riekkinen P, Rinne UK, Sonninen V.
    Acta Neurol Scand; 1974 Oct 12; 50(1):122-30. PubMed ID: 4365556
    [No Abstract] [Full Text] [Related]

  • 12. Behavioral effects of thyrotropin releasing hormone in animals and man: a generic hypothesis.
    Prange AJ, Wilson IC.
    Psychopharmacol Bull; 1975 Jan 12; 11(1):22-4. PubMed ID: 804704
    [No Abstract] [Full Text] [Related]

  • 13. DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF).
    Plotnikoff NP, Kastin AJ, Anderson MS, Schally AV.
    Life Sci I; 1971 Nov 15; 10(22):1279-83. PubMed ID: 4947365
    [No Abstract] [Full Text] [Related]

  • 14. Site of inactivation of melanocyte-stimulating hormone-release-inhibiting hormone by human plasma.
    Nair RM, Redding TW, Kastin AJ, Schally AV.
    Biochem Pharmacol; 1973 Aug 01; 22(15):1915-9. PubMed ID: 4578947
    [No Abstract] [Full Text] [Related]

  • 15. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
    Chan PL, Nutt JG, Holford NH.
    J Pharmacokinet Pharmacodyn; 2005 Aug 01; 32(3-4):307-31. PubMed ID: 16320098
    [Abstract] [Full Text] [Related]

  • 16. Structure-activity studies of MSH-release-inhibiting hormone.
    Celis ME, Hase S, Walter R.
    FEBS Lett; 1972 Nov 01; 27(2):327-30. PubMed ID: 4352026
    [No Abstract] [Full Text] [Related]

  • 17. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice.
    Huidobro-Toro JP, De Carolis AS, Longo VG.
    Pharmacol Biochem Behav; 1974 Nov 01; 2(1):105-9. PubMed ID: 4364044
    [No Abstract] [Full Text] [Related]

  • 18. Progress in understanding and treating Parkinson's disease.
    Barbeau A.
    Can J Neurol Sci; 1976 May 01; 3(2):81-4. PubMed ID: 773522
    [Abstract] [Full Text] [Related]

  • 19. The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
    Couto B, Oliveira C, Mattos JP, Freitas MR.
    Neurol Neurocir Psiquiatr; 1976 May 01; 17(4):285-92. PubMed ID: 798128
    [Abstract] [Full Text] [Related]

  • 20. [L-dopa with extracerebral dope-decarboxylase inhibitor (MK-486) in the treatment of Parkinson's disease. Preliminary evaluation of results].
    Pakszys W, Domzał T.
    Neurol Neurochir Pol; 1976 May 01; 10(3):345-52. PubMed ID: 951024
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.